<?xml version="1.0" encoding="UTF-8"?>
<p>The rate of treatment discontinuation in our study was 20% (15/74 patients). This is broadly in line with rates reported for R-CHOP [17% (43/242)] and VR-CAP [18.8% (45/240)] in older MCL patients treated in first line,
 <sup>
  <xref rid="b7-1040138" ref-type="bibr">7</xref>
 </sup> and is lower than that reported with the R-BAC500 regimen (33%)
 <sup>
  <xref rid="b24-1040138" ref-type="bibr">24</xref>
 </sup> (
 <italic>Online Supplementary Table S4</italic>). The reported rates of premature therapy cessation for the BR and R-CHOP regimens are 8% and 5%, respectively.
 <sup>
  <xref rid="b10-1040138" ref-type="bibr">10</xref>
 </sup>
</p>
